Company: CRVO
Filing Date: 2025-05-12
Form Type: 8-K
Source: 0001437749-25-016131
Chunk: 0

Company: CervoMed Inc.
Filing Date: 2025-05-12
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01      Entry into a Material Definitive Agreement  

On May 12, 2025, CervoMed Inc. (the “ Company”) entered into a sales agreement (the “ Sales Agreement”) with Leerink Partners LLC (the “ Sales Agent”), pursuant to which the Company may offer and sell, from time to time, shares (the “ Shares”) of its common stock, par value $0.001 per share, having an aggregate offering price of up to $50,000,000 through the Sales Agent, acting as agent.

Pursuant to the Sales Agreement, sales of the Shares may be made by any method permitted that is deemed to be an “at-the-market” offering as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “ Securities Act”), including sales made directly on or through The Nasdaq Capital Market or any other existing trading market for the shares, through a market maker, or, if expressly authorized by the Company, in negotiated transactions. The Sales Agent will use its commercially reasonable efforts, subject to the terms of the Sales Agreement, to sell all of the Shares requested to be sold by the Company. Under the Sales Agreement, the Sales Agent will be entitled to compensation of 3.0% of the aggregate gross proceeds of any Shares sold under the Sales Agreement. The Company has no obligation to sell any of the Shares under the Sales Agreement and may at any time and from time to time suspend the offering of the Shares under the Sales Agreement.

The Sales Agreement contains customary representations, warranties and covenants by the Company. The Company also agreed to provide indemnification and contribution to the Sales Agent against certain liabilities, including under the Securities Act and the Securities Exchange Act of 1934, as amended (the “ Exchange Act”).

Any sales of Shares under the Sales Agreement will be made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-282494), including the related prospectus, filed with the Securities and Exchange Commission on October 3, 2024 and declared effective on October 10, 2024, and the prospectus supplement that forms a part of the Registration Statement.

The foregoing description of certain provisions of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the Sales Agreement, which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Mintz,